GleamWall
中文EN

OGN Organon & Co.

Pharmaceutical Preparations · NYSE · SEC CIK 1821825 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-3.2%
TTM net income YoY-57.5%
TTM EPS YoY-59.2%
Revenue 3-yr CAGR-0.3%
Net income 3-yr CAGR-28.6%

Margins

Gross margin53.1%
Operating margin—
Net margin3.5%
FCF margin11.1%
EBITDA margin—

Returns

ROE20.3%
ROA1.6%
ROIC (approx.)—
Asset turnover0.45x

Leverage & solvency

Liabilities / assets91.1%
Debt / equity7.17x
Current ratio2.02x
Interest coverage—

Cash quality & payout

Operating cash flow / net income3.96x
Accruals ratio-4.7%
Payout ratio9.4%
Capex / revenue2.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$6.22B$6.40B
Cost of revenue$2.90B$2.69B
Gross profit$3.31B$3.71B
R&D expense$366.00M$469.00M
SG&A expense$1.72B$1.76B
Interest expense$504.00M$520.00M
Pretax income$425.00M$807.00M
Income tax$238.00M-$57.00M
Net income$187.00M$864.00M
EPS (basic)0.723.36
EPS (diluted)0.723.33
Dividends declared per share0.341.12
Weighted avg. shares (diluted)260.76M259.15M
Balance sheet
Cash & equivalents$574.00M$675.00M
Receivables$1.33B$1.36B
Inventory$1.41B$1.32B
Current assets$4.35B$4.35B
PP&E, net$1.30B$1.17B
Goodwill$4.15B$4.68B
Intangibles$1.13B$1.41B
Total assets$12.87B$13.10B
Current liabilities$2.39B$2.72B
Short-term debt$16.00M$20.00M
Long-term debt$8.63B$8.86B
Total debt$8.64B$8.88B
Total liabilities$12.12B$12.63B
Shareholders' equity$752.00M$472.00M
Net debt$8.07B$8.21B
Shares outstanding260.32M257.80M
Cash flow statement
Operating cash flow$700.00M$939.00M
Capital expenditure$162.00M$175.00M
Free cash flow$538.00M$764.00M
Investing cash flow-$390.00M-$513.00M
Financing cash flow-$561.00M-$368.00M
Depreciation & amortization$156.00M$132.00M
Stock-based compensation$77.00M$105.00M
Dividends paid$88.00M$297.00M

Free plan shows the latest 2 periods; Pro shows all 7 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.